{"id":57969,"date":"2025-09-11T12:04:48","date_gmt":"2025-09-11T06:34:48","guid":{"rendered":"https:\/\/mint-money.in\/index.php\/2025\/09\/11\/raainbow-phase-2-3-paediatric-alopecia-areata-trial-featuring-cliniexperts-research-services-published-in-british-journal-of-dermatology\/"},"modified":"2025-09-11T12:04:48","modified_gmt":"2025-09-11T06:34:48","slug":"raainbow-phase-2-3-paediatric-alopecia-areata-trial-featuring-cliniexperts-research-services-published-in-british-journal-of-dermatology","status":"publish","type":"post","link":"https:\/\/mint-money.in\/index.php\/2025\/09\/11\/raainbow-phase-2-3-paediatric-alopecia-areata-trial-featuring-cliniexperts-research-services-published-in-british-journal-of-dermatology\/","title":{"rendered":"RAAINBOW Phase 2\/3 Paediatric Alopecia Areata Trial Featuring CliniExperts Research Services Published in British Journal of Dermatology"},"content":{"rendered":"<div>\n<p><strong><span dir=\"LTR\">New Delhi [India], September 11:\u00a0<\/span><\/strong><span dir=\"LTR\"> CliniExperts Research Services is proud to announce its contribution to the <\/span><strong><span dir=\"LTR\">RAAINBOW Phase 2\/3 global clinical trial<\/span><\/strong><span dir=\"LTR\">, evaluating Cinainu, the world\u2019s first botanical topical drug candidate for the treatment of <\/span><strong><span dir=\"LTR\">moderate to severe paediatric Alopecia Areata (AA)<\/span><\/strong><span dir=\"LTR\">. The groundbreaking results have been published in the British Journal of Dermatology on 16th of July, 2025.\u00a0<\/span><\/p>\n<p><span dir=\"LTR\">CliniExperts Research Services played a key role in conducting the India arm of the trial, managing\u00a0<\/span><strong><span dir=\"LTR\">clinical operations across multiple sites, data analysis, and reporting<\/span><\/strong><span dir=\"LTR\">, in collaboration with\u00a0<\/span><strong><span dir=\"LTR\">Legacy Healthcare<\/span><\/strong><span dir=\"LTR\">, the Switzerland-based biopharmaceutical company leading the trial.<\/span><\/p>\n<h2><strong><span dir=\"LTR\">About Paediatric Alopecia Areata &amp; Cinainu<\/span><\/strong><\/h2>\n<p><span dir=\"LTR\">Alopecia Areata (AA) is an autoimmune disorder causing patchy hair loss, with limited safe treatment options for children. Cinainu is a patented\u00a0<\/span><strong><span dir=\"LTR\">botanical topical solution<\/span><\/strong><span dir=\"LTR\">\u00a0targeting inflammation, apoptosis, and oxidative stress in AA physiology.<\/span><\/p>\n<h2><strong><span dir=\"LTR\">About the RAAINBOW Trial<\/span><\/strong><\/h2>\n<p>\u25cf<strong><span dir=\"LTR\">multinational, randomized, double-blind, placebo-controlled, multicentric Phase 2\/3 trial<\/span><\/strong><span dir=\"LTR\">\u00a0in paediatric AA.<\/span><span dir=\"LTR\"><br \/>\n<\/span><\/p>\n<p>\u25cf<span dir=\"LTR\">Conducted across\u00a0<\/span><strong><span dir=\"LTR\">12 sites in 4 countries<\/span><\/strong><span dir=\"LTR\">\u00a0with\u00a0<\/span><strong><span dir=\"LTR\">107 patients aged 2\u201318 years<\/span><\/strong><span dir=\"LTR\"><br \/>\n<\/span><\/p>\n<p>\u25cf<strong><span dir=\"LTR\">India\u2019s contribution:<\/span><\/strong><span dir=\"LTR\"> Led by CliniExperts Research Services, which ensured compliance with safety, regulatory, and quality standards while delivering comprehensive data analysis.<\/span><\/p>\n<p>\u25cf<strong><span dir=\"LTR\">Results of the trial are available on the\u00a0<\/span><\/strong><a href=\"https:\/\/academic.oup.com\/bjd\/advance-article\/doi\/10.1093\/bjd\/ljaf279\/8203556?login=false\" target=\"_blank\" rel=\"noopener\"><strong><u><span dir=\"LTR\">BJD website\u00a0<\/span><\/u><\/strong><\/a><\/p>\n<h2><strong><span dir=\"LTR\">Leadership Voices<\/span><\/strong><\/h2>\n<p><span dir=\"LTR\"><strong>Saad Harti, Founder &amp; CEO, Legacy Healthcare,<\/strong> said, \u201cBeyond its efficacy in regrowing patients\u2019 scalp hair, Cinainu has been shown to treat this autoimmune disease without immunosuppression-related adverse events, and with persistent efficacy, which, to our knowledge, is a first.\u00a0Publication in the British Journal of Dermatology marks a key milestone supporting Cinainu\u2019s efficacy and safety.\u201d<\/span><\/p>\n<p><strong><span dir=\"LTR\">CliniExperts Research Services<\/span><\/strong><span dir=\"LTR\"> stated, \u201cWe are honoured to have contributed to the successful execution of the Indian arm of this global trial. Our role in ensuring quality conduct and delivering country-specific trial design demonstrates CliniExperts\u2019 growing leadership in global dermatology research.\u201d<\/span><\/p>\n<h2><strong><span dir=\"LTR\">About Legacy Healthcare<\/span><\/strong><\/h2>\n<p><span dir=\"LTR\">Legacy Healthcare is a Switzerland-based biopharmaceutical company pioneering safe, plant-based therapeutics for chronic diseases.<\/span><\/p>\n<h2><strong><span dir=\"LTR\">About CliniExperts Research Services<\/span><\/strong><\/h2>\n<p><span dir=\"LTR\">CliniExperts Research Services is a leading clinical research organization based in India, specializing in high-quality clinical operations, regulatory expertise, and data analysis across multiple therapeutic areas. Its strong commitment to innovation and compliance enables global biopharmaceutical partners to achieve breakthrough outcomes.<\/span><\/p>\n<p><span dir=\"LTR\">To know more details, please visit: <\/span><a href=\"https:\/\/cliniexperts-research.com\/news\/cliniexperts-research-services-contributes-to-the-success-of-global-paediatric-alopecia\/\" target=\"_blank\" rel=\"noopener\"><u><span dir=\"LTR\">CliniExperts Research \u00a0Services\u00a0<\/span><\/u><\/a><\/p>\n<p><em>If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>New Delhi [India], September 11:\u00a0 CliniExperts Research Services is proud to announce its contribution to the RAAINBOW Phase 2\/3 global clinical trial, evaluating Cinainu, the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":57970,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[243,242],"class_list":["post-57969","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","tag-pr","tag-press-release"],"_links":{"self":[{"href":"https:\/\/mint-money.in\/index.php\/wp-json\/wp\/v2\/posts\/57969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mint-money.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mint-money.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mint-money.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mint-money.in\/index.php\/wp-json\/wp\/v2\/comments?post=57969"}],"version-history":[{"count":0,"href":"https:\/\/mint-money.in\/index.php\/wp-json\/wp\/v2\/posts\/57969\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mint-money.in\/index.php\/wp-json\/wp\/v2\/media\/57970"}],"wp:attachment":[{"href":"https:\/\/mint-money.in\/index.php\/wp-json\/wp\/v2\/media?parent=57969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mint-money.in\/index.php\/wp-json\/wp\/v2\/categories?post=57969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mint-money.in\/index.php\/wp-json\/wp\/v2\/tags?post=57969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}